<DOC>
	<DOCNO>NCT00581997</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , mechanism action multiple dos QAX576 patient pulmonary fibrosis secondary systemic sclerosis</brief_summary>
	<brief_title>QAX576 Patients With Pulmonary Fibrosis Secondary Systemic Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<criteria>Men woman age 18 65 year confirm diagnosis pulmonary fibrosis secondary systemic sclerosis Both men woman must willing use two form contraception . Additional information regard requirement available screen Certain medical condition may exclude patient participation . Should participate another clinical study within 4 week study start Smokers eligible participation Blood loss donation 400 mL within 2 month study start Pregnant woman woman breast feed Past medical history clinically significant ECG abnormality Connective tissue disorder systemic sclerosis . Active infection history systemic parasitic infection History immunodeficiency disease , include positive HIV test result History drug alcohol abuse within 12 month study start Any condition may compromise patient safety Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Pulmonary fibrosis , systemic sclerosis</keyword>
</DOC>